Michiel T. Van Zeijl

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.

Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: December 09, 2022

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.

Journal: Melanoma research

Published: June 15, 2022

Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.

Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.

Journal: Annals of internal medicine

Published: February 15, 2021

Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice.

Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice.

Journal: International journal of cancer

Published: November 26, 2020

Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.

Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: August 18, 2020

Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry.

Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry.

Journal: Journal of geriatric oncology

Published: August 02, 2020

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease.

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease.

Journal: ESMO open

Published: July 24, 2020

Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study.

Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 11, 2020

Real-world outcomes of advanced melanoma patients not represented in phase III trials.

Real-world outcomes of advanced melanoma patients not represented in phase III trials.

Journal: International journal of cancer

Published: February 23, 2020

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 09, 2019

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?

Journal: Cancers

Published: October 06, 2019

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

Journal: Cancers

Published: May 27, 2019

Showing 1-12 of 16

Last Updated: 09/26/2026